Eton Pharmaceuticals Secures U.S. Rights to Aquestive’s LIBERVANT for Seizure Rescue
Event summary
- Eton Pharmaceuticals gains exclusive U.S. commercialization rights to LIBERVANT, a buccal film for seizure rescue, from Aquestive Therapeutics.
- Product launch anticipated in April 2027, pending final FDA approval, with a $450M+ U.S. market opportunity.
- LIBERVANT holds Orphan Drug Designation and patent protection extending to 2038.
- Patient research shows 71% preference for buccal film over nasal spray, assuming equivalent efficacy.
The big picture
Eton’s deal for LIBERVANT expands its rare disease portfolio into neurology, aligning with its strategy of acquiring differentiated specialty medicines. The agreement underscores the growing demand for portable, patient-friendly seizure rescue treatments, as evidenced by strong preference data. With patent protection secured through 2038, Eton aims to establish a durable revenue stream in a market exceeding $450M annually.
What we're watching
- Regulatory Timing
- Whether LIBERVANT secures full FDA approval by January 2027, clearing the path for commercial launch.
- Market Penetration
- How Eton leverages its rare disease expertise to compete against established seizure rescue therapies like VALTOCO.
- Patient Adoption
- The pace at which patients and caregivers shift from nasal/rectal treatments to the buccal film format.
Related topics